SpectraCure AB - Asset Resilience Ratio
SpectraCure AB (SPEC) has an Asset Resilience Ratio of 12.95% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SpectraCure AB current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how SpectraCure AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SPEC total asset value.
Liquid Assets Composition Over Time
This chart breaks down SpectraCure AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of SpectraCure AB for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr13.53 Million | 12.95% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr13.53 Million | 12.95% |
Asset Resilience Insights
- Moderate Liquidity: SpectraCure AB has 12.95% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
SpectraCure AB Industry Peers by Asset Resilience Ratio
Compare SpectraCure AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Stratec SE
XETRA:SBS |
Medical Devices | 0.29% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
DRTECH Corporation
KQ:214680 |
Medical Devices | 5.18% |
|
Novacyt
PA:ALNOV |
Medical Devices | 0.02% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.48% |
Annual Asset Resilience Ratio for SpectraCure AB (2016–2025)
The table below shows the annual Asset Resilience Ratio data for SpectraCure AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.95% | Skr13.53 Million ≈ $1.46 Million |
Skr104.47 Million ≈ $11.24 Million |
-2.16pp |
| 2024-12-31 | 15.10% | Skr18.27 Million ≈ $1.97 Million |
Skr121.00 Million ≈ $13.02 Million |
-24.22pp |
| 2023-12-31 | 39.32% | Skr56.95 Million ≈ $6.13 Million |
Skr144.83 Million ≈ $15.59 Million |
-18.05pp |
| 2022-12-31 | 57.37% | Skr93.18 Million ≈ $10.03 Million |
Skr162.42 Million ≈ $17.48 Million |
-10.70pp |
| 2021-12-31 | 68.07% | Skr129.69 Million ≈ $13.96 Million |
Skr190.52 Million ≈ $20.50 Million |
-6.61pp |
| 2020-12-31 | 74.69% | Skr157.24 Million ≈ $16.92 Million |
Skr210.53 Million ≈ $22.66 Million |
+20.58pp |
| 2019-12-31 | 54.10% | Skr54.21 Million ≈ $5.83 Million |
Skr100.19 Million ≈ $10.78 Million |
-11.27pp |
| 2018-12-31 | 65.38% | Skr45.08 Million ≈ $4.85 Million |
Skr68.95 Million ≈ $7.42 Million |
+48.79pp |
| 2017-12-31 | 16.59% | Skr2.44 Million ≈ $262.60K |
Skr14.71 Million ≈ $1.58 Million |
+15.26pp |
| 2016-12-31 | 1.33% | Skr381.67K ≈ $41.07K |
Skr28.77 Million ≈ $3.10 Million |
-- |
About SpectraCure AB
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.